Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Work In Process (2016 - 2025)

Historic Work In Process for Ocular Therapeutix (OCUL) over the last 12 years, with Q4 2025 value amounting to $1.7 million.

  • Ocular Therapeutix's Work In Process rose 1558.09% to $1.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.7 million, marking a year-over-year increase of 1558.09%. This contributed to the annual value of $1.7 million for FY2025, which is 1558.09% up from last year.
  • Ocular Therapeutix's Work In Process amounted to $1.7 million in Q4 2025, which was up 1558.09% from $1.4 million recorded in Q3 2025.
  • Over the past 5 years, Ocular Therapeutix's Work In Process peaked at $1.8 million during Q1 2025, and registered a low of $402000.0 during Q1 2021.
  • Moreover, its 5-year median value for Work In Process was $907000.0 (2022), whereas its average is $995800.0.
  • Its Work In Process has fluctuated over the past 5 years, first skyrocketed by 65066.67% in 2021, then tumbled by 292.86% in 2025.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Work In Process stood at $605000.0 in 2021, then surged by 48.6% to $899000.0 in 2022, then rose by 12.57% to $1.0 million in 2023, then soared by 47.13% to $1.5 million in 2024, then rose by 15.58% to $1.7 million in 2025.
  • Its Work In Process stands at $1.7 million for Q4 2025, versus $1.4 million for Q3 2025 and $1.7 million for Q2 2025.